9 results about "Tumor necrosis factor α" patented technology

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The invention discloses an application of sodium bicarbonate in preparation of a tumor immune drug enhancer. The molecular formula of the sodium bicarbonate is NaHCO3. Tumor necrosis factor alpha (TNF-alpha) is used as an anti-tumor drug to treat tumors, however, the anti-tumor efficacy of the TNF-alpha is unpredictable. It is proved that TNF-alpha activates a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells, NF-kappa B) signal channel, inflammatory response is enhanced, tumor cell growth is promoted, and the TNF-alpha can activate a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells (NF-kappa B) signal channel. Under the action of sodium bicarbonate, a TNF-alpha mediated NF-kappa B signal channel is inhibited, a TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) dependent Necroptosis signal channel is activated, and the death of tumor cells is caused, so that the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) depends on the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) and the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1). The prepared medicine contains a medicine excipient or a carrier allowed by a preparation. The invention develops new application of sodium bicarbonate in preparation of medicines for treating tumors. And the medicine is non-toxic to a human body after being administrated in a tumor body. Sodium bicarbonate can be used for preparing a reinforcing agent of TNF-alpha.

The present disclosure is directed to fusion proteins comprising a Tumor Necrosis Factor α (TNFα) binding protein and an interleukin-10 (IL-10) molecule, methods of making the fusion proteins, and methods of treating or preventing autoimmune and inflammatory conditions using the fusion proteins.

The present invention discloses a marine galacto-oligosaccharide lipid and its preparation method and application, which belongs to the field of marine biological resource utilization and drug development. The present invention combines the marine red algae polysaccharide degradation technology with the high efficiency of reductive amination fatty chain modification for the first time, and realizes the modification of saturated fatty chains of different lengths of marine galacto-oligosaccharides with different polymerization degrees. And through cell-level pharmacodynamic evaluation, it is proved that marine galacto-oligosaccharide lipid can significantly inhibit the release of nitric oxide and the expression of inflammatory factors such as interleukin-6 and tumor necrosis factor α in microglia, and has the activity of inhibiting neuroinflammatory; at the same time, it can significantly inhibit the proliferation of tumor cells U87MG and GL261, has certain anti-tumor potential, and can be used to prepare drugs for preventing and / or treating neuroinflammation and anti-tumor related diseases. Therefore, the marine galacto-oligosaccharide lipid prepared by the present invention has high clinical application value and development prospects.

The present disclosure provides a bispecific antibody, comprising: a first domain that specifically binds TNF-like ligand 1a (TL1A), and a second domain that specifically binds tumor necrosis factor α (TNF-α). The present disclosure also provides a method of the bispecific antibodies for the treatment or prevention of diseases associated with TL1A and / or TNF-α.

Aiming at the current situation that probiotics are used for treating periodontitis in the prior art, the invention provides a strain of mixed Weissella confusa LHJY. The mixed Weissella confusa is named as a mixed Weissella confusa LHJY strain, and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 20251930, and the preservation date is September 1, 2025. The method comprises the following steps: separating and purifying a pickled vegetable sample by an inventor to obtain probiotic mixed Weissella LHJY; a bacteriostatic experiment and a biological membrane removal experiment detect that the confused Weissella sp. LHJY has a remarkable inhibition effect on important periodontal pathogenic bacteria, namely porphyromonas gingivalis (P. gingivalis) and fusobacterium nucleatum (F. nucleatum), and fills up the blank of application of the confused Weissella sp. To treatment of periodontitis in the prior art, and the confused Weissella sp. LHJY has a remarkable inhibition effect on the periodontal pathogenic bacteria, namely porphyromonas gingivalis (P. gingivalis) and fusobacterium nucleatum (F. nucleatum). Moreover, the confused Weissella sp. LHJY can tolerate lysozyme with a relatively high concentration, effectively reduces the expression of inflammatory factors including interleukin 1 beta, tumor necrosis factor alpha and interleukin 6 in an inflammatory cell model, and has an important application prospect in the aspects of inhibiting periodontal disease pathogenic bacteria and regulating immune response.

In view of the current situation of probiotics for periodontitis treatment in the prior art, the application provides a Weissella confusa LHJY. The Weissella confusa LHJY strain is named as Weissella confusa LHJY strain, is preserved in the China Center for Type Culture Collection, and has a preservation number of CCTCC NO: M 20251930 and a preservation date of September 1, 2025. The inventors isolate and purify the probiotic Weissella confusa LHJY from a pickled vegetable sample; and find that the Weissella confusa LHJY has a significant inhibitory effect on P. gingivalis and F. nucleatum, which are important periodontal pathogenic bacteria, through a bacteriostatic experiment and a biofilm removal experiment, thereby filling the blank of application of the Weissella confusa to periodontitis treatment in the prior art. Moreover, the Weissella confusa LHJY can tolerate a high concentration of lysozyme, effectively reduces the expression of interleukin 1β, tumor necrosis factor α and interleukin 6 inflammatory factors in an inflammatory cell model, and has an important application prospect in inhibiting periodontal disease pathogenic bacteria and regulating immune responses.

This invention provides a fused pentacyclic imidazole compound or its tautomers, stereoisomers or pharmaceutically acceptable salts thereof, as well as its preparation method and applications. These compounds are regulators of tumor necrosis factor α (TNFα) signaling, possess excellent pharmacokinetic properties, and have potential applications in the treatment of adverse inflammatory and autoimmune diseases, pain and nociceptive disorders, neurological and neurodegenerative diseases, cardiovascular diseases, metabolic diseases, tumors, and eye diseases.

This invention discloses the application of the Siegesbeckia orientalis composition in the preparation of drugs to improve cognitive impairment after heart failure (CHF). The composition consists of Astragalus membranaceus extract, Siegesbeckia orientalis extract, and Periploca sepium extract. Experiments have shown that the Siegesbeckia orientalis composition can significantly improve spatial memory and working memory in CHF rats, and improve cognitive function; it can significantly inhibit the release of tumor necrosis factor α and interleukin 1β in the hippocampus of CHF rats, and increase the release of interleukin 10 and brain-derived neurotrophic factor; it can significantly reduce the loss and damage of Nissl bodies in the brain tissue of CHF rats; and it can significantly improve the ultrastructure of neurons in the hippocampus of CHF rats, regulate synaptic plasticity, and promote the growth of dendrites and dendritic spines.